Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lanting Liu

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
Frontiers in Immunology|October 9, 2024
DNp73 enhances tumor progression and immune evasion in multiple myeloma by targeting the MYC and MYCN pathwaysLanting Liu, Dasen Gong, Hao Sun, et al.
Haematologica|May 30, 2024
LILRB4 represents a promising target for immunotherapy by dual targeting tumor cells and myeloid-derived suppressive cells in multiple myelomaLixin Gong, Hao Sun, Lanting Liu, et al.
Scientific Reports|November 26, 2020
Multiple myeloma hinders erythropoiesis and causes anaemia owing to high levels of CCL3 in the bone marrow microenvironmentLanting Liu, Zhen Yu, Hui Cheng, et al.
Oncogenesis|March 7, 2020
Cdc37 suppression induces plasma cell immaturation and bortezomib resistance in multiple myeloma via Xbp1sMeirong Zang, Jiaojiao Guo, Lanting Liu, et al.
Ebiomedicine|March 28, 2022
Indirubin-3'-monoxime acts as proteasome inhibitor: Therapeutic application in multiple myelomaZhen Yu, Xiaojing Wei, Lanting Liu, et al.
Molecular Cancer Research : MCR|April 22, 2020
Polycomb-like Protein 3 Induces Proliferation and Drug Resistance in Multiple Myeloma and Is Regulated by miRNA-15aTengteng Yu, Chenxing Du, Xiaoke Ma, et al.
Leukemia & Lymphoma|December 18, 2019
1q21 gain but not t(4;14) indicates inferior outcomes in multiple myeloma treated with bortezomibChenxing Du, Xuehan Mao, Yan Xu, et al.
Blood Advances|October 15, 2021
Clonal phylogeny and evolution of critical cytogenetic aberrations in multiple myeloma at single-cell level by QM-FISHYuting Yan, Xiaoqi Qin, Jiahui Liu, et al.
Blood|March 19, 2020
YWHAE/14-3-3ε expression impacts the protein load, contributing to proteasome inhibitor sensitivity in multiple myelomaYan Xu, Mariateresa Fulciniti, Mehmet K Samur, et al.
The Journal of Clinical Investigation|December 9, 2021
Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphomaShuhua Yi, Yuting Yan, Meiling Jin, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Frontiers in Immunology|October 9, 2024
DNp73 enhances tumor progression and immune evasion in multiple myeloma by targeting the MYC and MYCN pathwaysLanting Liu, Dasen Gong, Hao Sun, et al.
Haematologica|May 30, 2024
LILRB4 represents a promising target for immunotherapy by dual targeting tumor cells and myeloid-derived suppressive cells in multiple myelomaLixin Gong, Hao Sun, Lanting Liu, et al.
Scientific Reports|November 26, 2020
Multiple myeloma hinders erythropoiesis and causes anaemia owing to high levels of CCL3 in the bone marrow microenvironmentLanting Liu, Zhen Yu, Hui Cheng, et al.
Oncogenesis|March 7, 2020
Cdc37 suppression induces plasma cell immaturation and bortezomib resistance in multiple myeloma via Xbp1sMeirong Zang, Jiaojiao Guo, Lanting Liu, et al.
Ebiomedicine|March 28, 2022
Indirubin-3'-monoxime acts as proteasome inhibitor: Therapeutic application in multiple myelomaZhen Yu, Xiaojing Wei, Lanting Liu, et al.
Molecular Cancer Research : MCR|April 22, 2020
Polycomb-like Protein 3 Induces Proliferation and Drug Resistance in Multiple Myeloma and Is Regulated by miRNA-15aTengteng Yu, Chenxing Du, Xiaoke Ma, et al.
Leukemia & Lymphoma|December 18, 2019
1q21 gain but not t(4;14) indicates inferior outcomes in multiple myeloma treated with bortezomibChenxing Du, Xuehan Mao, Yan Xu, et al.
Blood Advances|October 15, 2021
Clonal phylogeny and evolution of critical cytogenetic aberrations in multiple myeloma at single-cell level by QM-FISHYuting Yan, Xiaoqi Qin, Jiahui Liu, et al.
Blood|March 19, 2020
YWHAE/14-3-3ε expression impacts the protein load, contributing to proteasome inhibitor sensitivity in multiple myelomaYan Xu, Mariateresa Fulciniti, Mehmet K Samur, et al.
The Journal of Clinical Investigation|December 9, 2021
Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphomaShuhua Yi, Yuting Yan, Meiling Jin, et al.
Pageof 3